162 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
not to remove from the Company’s premises any property of the PLC or any Group Company including, but not limited to, documents, records, or materials … Executive discovers this is incorrect, Executive shall promptly return any such materials to Executive’s former employer. The Company does not want
8-K
EX-10.1
7umyrmi1j f6
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
5rzdm91aihu7v oq1y
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
sw5c3y56 j78okmmof
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
olg3was7
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
b2m n5qmt
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
wc0g59c1vl4dwela 6tq
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
li4ccbh jkxa
30 May 23
Business combination disclosure
4:21pm
8-K
whgp0i88 j8c
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
ehm97pb8zja3a6iuiu
22 May 23
Business combination disclosure
7:01am
8-K
6vzvnvth 7n9r
22 May 23
Other Events
6:59am
8-K
EX-99.1
w63aybhw5 nmup2v9
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
yj6 s0wjczb4
20 Apr 23
Prospectus supplement
4:32pm